NASDAQ:TTOO - T2 Biosystems Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$6.49 -0.07 (-1.07 %)
(As of 08/17/2018 04:09 AM ET)
Previous Close$6.56
Today's Range$6.39 - $6.68
52-Week Range$3.60 - $9.98
Volume317,300 shs
Average Volume567,220 shs
Market Capitalization$283.18 million
P/E RatioN/A
Dividend YieldN/A
Beta1.07
T2 Biosystems logoT2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications, as well as T2Candida panel for the detection of candida species in human whole blood specimens. In addition, it is developing T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2Lyme for the detection of various strains of Lyme disease-causing bacteria; and T2Plex, an integrated instrument for hemostasis applications. The company has collaboration agreement with Canon U.S. Life Sciences, Inc. to develop a novel diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC for the direct detection diagnostic test panel that adds additional bacteria species to the existing T2Bacteria product candidate and testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Receive TTOO News and Ratings via Email

Sign-up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TTOO
CUSIPN/A
Phone781-761-4646

Debt

Debt-to-Equity Ratio1.22
Current Ratio7.31
Quick Ratio7.10

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.66 million
Price / Sales60.96
Cash FlowN/A
Price / CashN/A
Book Value$0.04 per share
Price / Book162.25

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-62,420,000.00
Net Margins-637.62%
Return on Equity-556.22%
Return on Assets-91.71%

Miscellaneous

Employees161
Outstanding Shares43,770,000
Market Cap$283.18 million

T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions

What is T2 Biosystems' stock symbol?

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

How were T2 Biosystems' earnings last quarter?

T2 Biosystems Inc (NASDAQ:TTOO) posted its quarterly earnings data on Thursday, August, 2nd. The medical equipment provider reported ($0.32) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.32). The medical equipment provider had revenue of $3.90 million for the quarter, compared to the consensus estimate of $2.97 million. T2 Biosystems had a negative net margin of 637.62% and a negative return on equity of 556.22%. The firm's revenue was up 307.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.50) EPS. View T2 Biosystems' Earnings History.

When is T2 Biosystems' next earnings date?

T2 Biosystems is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for T2 Biosystems.

What price target have analysts set for TTOO?

5 brokerages have issued 1-year target prices for T2 Biosystems' stock. Their forecasts range from $5.20 to $14.00. On average, they expect T2 Biosystems' share price to reach $8.40 in the next twelve months. This suggests a possible upside of 29.4% from the stock's current price. View Analyst Price Targets for T2 Biosystems.

What is the consensus analysts' recommendation for T2 Biosystems?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for T2 Biosystems.

What are Wall Street analysts saying about T2 Biosystems stock?

Here are some recent quotes from research analysts about T2 Biosystems stock:
  • 1. According to Zacks Investment Research, "T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts. " (8/9/2018)
  • 2. HC Wainwright analysts commented, "We note that T2Bacteria identifies five of the most common and deadly sepsis-causing species of bacteria, has 90% sensitivity and 98% specificity, and is the first FDA-cleared test to identify sepsis-causing bacteria directly from whole blood. Importantly, T2Bacteria provides test results in approximately five hours, which is more than 2.5 days faster than blood culture-dependent tests. This difference in time-to-result is clinically meaningful since rapid targeted treatment based on identification of causative pathogens is critical for clinical outcome, and every hour saved in time to implement a targeted therapy could decrease patient mortality by 8%, according to published literature." (5/30/2018)

Who are some of T2 Biosystems' key competitors?

Who are T2 Biosystems' key executives?

T2 Biosystems' management team includes the folowing people:
  • Mr. John P. McDonough, CEO, Pres & Director (Age 58)
  • Prof. Michael J. Cima, Co-Founder & Director (Age 58)
  • Dr. Thomas J. Lowery Jr., Chief Scientific Officer (Age 39)
  • Mr. Lee Josephson, Co-Founder & Member of Scientific Advisory Board
  • Mr. John M. Sprague, CFO & Sr. VP (Age 59)

Has T2 Biosystems been receiving favorable news coverage?

News headlines about TTOO stock have been trending positive recently, Accern reports. The research group scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. T2 Biosystems earned a coverage optimism score of 0.25 on Accern's scale. They also gave news stories about the medical equipment provider an impact score of 46.42 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for T2 Biosystems.

Who are T2 Biosystems' major shareholders?

T2 Biosystems' stock is owned by a number of of retail and institutional investors. Top institutional investors include Senvest Management LLC (6.09%), Polaris Venture Management Co. V L.L.C. (4.21%), BlackRock Inc. (4.17%), Millennium Management LLC (2.69%), Renaissance Technologies LLC (1.88%) and Ardsley Advisory Partners (1.72%). Company insiders that own T2 Biosystems stock include Darlene M Deptula-Hicks, David B Elsbree, Joanne Spadoro, Michael Terrence Gibbs and Stanley Lapidus. View Institutional Ownership Trends for T2 Biosystems.

Which institutional investors are selling T2 Biosystems stock?

TTOO stock was sold by a variety of institutional investors in the last quarter, including Polaris Venture Management Co. V L.L.C. and Senvest Management LLC. View Insider Buying and Selling for T2 Biosystems.

Which institutional investors are buying T2 Biosystems stock?

TTOO stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Ardsley Advisory Partners, Renaissance Technologies LLC, Emerald Mutual Fund Advisers Trust, EAM Investors LLC, Point72 Asset Management L.P. and EAM Global Investors LLC. Company insiders that have bought T2 Biosystems stock in the last two years include Darlene M Deptula-Hicks, David B Elsbree, Joanne Spadoro and Michael Terrence Gibbs. View Insider Buying and Selling for T2 Biosystems.

How do I buy shares of T2 Biosystems?

Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is T2 Biosystems' stock price today?

One share of TTOO stock can currently be purchased for approximately $6.49.

How big of a company is T2 Biosystems?

T2 Biosystems has a market capitalization of $283.18 million and generates $4.66 million in revenue each year. T2 Biosystems employs 161 workers across the globe.

How can I contact T2 Biosystems?

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at 781-761-4646 or via email at [email protected]


MarketBeat Community Rating for T2 Biosystems (NASDAQ TTOO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  238 (Vote Outperform)
Underperform Votes:  195 (Vote Underperform)
Total Votes:  433
MarketBeat's community ratings are surveys of what our community members think about T2 Biosystems and other stocks. Vote "Outperform" if you believe TTOO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTOO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/17/2018 by MarketBeat.com Staff

Featured Article: What does RSI mean?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.